Course of uveitis in children with juvenile idiopathic arthritis (JIA): Five years follow-up data from a prospective multicenter Inception Cohort of Newly diagnosed patients with JIA (ICON-JIA) study
Authors' conclusion
Despite intensified DMARD treatment, almost half of the children experience JIAU-related ocular complications after 5 years of disease; however, visual acuity mostly remains good. Uveitis inactivity can be achieved frequently, but is often limited in duration. Lower JIA activity appears to correlate with uveitis inactivity on and off medication.
Study context
- Population
- Children with JIA-associated uveitis with onset after enrollment in the ICON-JIA inception cohort of newly diagnosed JIA, with documentation at 5-year follow-up
- Participants
- 75 children
- Outcome
- Uveitis characteristics, frequency and predictors of inactivity on medication (inactive uveitis ≥ 6 months) and inactivity off medication (inactive uveitis ≥ 6 months off medication)
- Follow-up
- 5 years
Methodological detailsmulticenter, inception cohort, 5-year follow-up
- Multicenter
- Inception cohort
- 5-year follow-up
Main finding
As reported in the abstract
Uveitis course to 5yFU
- Uveitis inactive at 5yFU
- 85.3%
- Still receiving disease-modifying antirheumatic drugs (DMARDs) at 5yFU
- 77.3%
- ≥ one episode of inactivity on medication until 5yFU
- 82.7%
- Inactivity on medication once
- 30.7%
- Inactivity on medication twice
- 37.3%
- Inactivity on medication three or more times
- 14.7%
- ≥ one episode of inactivity off medication until 5yFU
- 17.3%
Observational data: associations, not effects.
Further findings
Visual acuity at 5yFU
- Eyes with LogMAR < 0.1
- 65.5%
- Mean LogMAR (± SD)
- 0.11 ± 0.31
Ocular surgery and complications until 5yFU
- Ocular surgery required
- 5%
- Ocular complications
- 46.7%
Original publication
Course of uveitis in children with juvenile idiopathic arthritis (JIA): Five years follow-up data from a prospective multicenter Inception Cohort of Newly diagnosed patients with JIA (ICON-JIA) study. Arthritis Res Ther. Published 20 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →